Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
22OCT

UK Horizon Europe share rebounds to 9.3%

3 min read
16:30UTC

DSIT data published on 5 June show the UK's Horizon Europe funding share rose to 9.3% in 2024 from 5.8% a year earlier, with the applied-research strand up 68%, a genuine recovery that still sits below the pre-Brexit peak.

TechnologyDeveloping
Key takeaway

UK Horizon Europe recovery is real and feeds the spinout pipeline, but sits below the 2018/19 peak.

DSIT published UK participation figures for the EU's Horizon Europe research programme on Friday 5 June. The UK's share of funding won rose to 9.3% in 2024, from 5.8% in 2023, worth €994m, with its share of proposals climbing from 18.9% to 24.1%. The department described the result as a partial recovery toward late Horizon 2020 levels, still below the 2018/19 peak.⁠1

Horizon Europe is the EU's flagship research programme; the UK re-associated in 2024 after Brexit exclusion. The sharpest move sits in Pillar 2, the strand funding industrial and applied collaborative research that feeds university tech-transfer offices and spinouts. The UK's Pillar 2 share rose 68% year on year, from 3.7% to 6.2%. The part of the recovery most likely to surface later as commercial IP is also the part growing fastest.

DSIT's own framing keeps the ceiling in view. Re-association has reopened the collaborative-funding pipe, but it is not yet running at pre-Brexit volume. The France science alliance signed in May is the bilateral hedge that runs alongside the multilateral programme, a second channel for the same collaborative research while Horizon participation climbs back toward where it was.

Deep Analysis

In plain English

Horizon Europe is the European Union's main research funding programme, with a total budget of roughly €95bn for 2021-2027. The UK was excluded from it after Brexit until re-association in early 2024. In 2023, the UK's share of Horizon funding was 5.8%. In 2024, it recovered to 9.3%, meaning UK researchers won €994m of grants. The applied-research strand (Pillar 2) recovered fastest, growing 68% year-on-year. However, DSIT itself describes this as a partial recovery: before Brexit, the UK had a larger share. Getting back to pre-Brexit levels requires winning a higher proportion of the proposals that UK researchers are submitting, which depends partly on Brussels relationships that were disrupted during three years of exclusion.

Deep Analysis
Root Causes

Pillar 2 (industrial research consortia) recovered faster than Pillar 1 (curiosity-driven ERC) for structural reasons. Pillar 2 projects involve industrial consortia where UK companies remain commercially attractive partners regardless of political status. A German automotive manufacturer running a battery electrolyte consortium has direct commercial reasons to include a UK material-science team even under associate rules.

ERC individual grants differ: UK researchers compete head-to-head against EU nationals in peer-review panels where the 2021-2023 exclusion period broke the informal network ties that referees use to assess applicants. Rebuilding those networks takes the length of a grant cycle, roughly 5-7 years, which is why the Pillar 1 recovery lags.

What could happen next?
  • Consequence

    Pillar 2 grants awarded in 2024 will produce commercial IP and spinout companies in 2029-2032. The 68% year-on-year growth means the UK spinout pipeline from Horizon is growing again after a four-year gap.

  • Risk

    The UK's 24.1% proposal share suggests strong research intent but a still-recovering award conversion rate. If consortium-formation biases persist, the actual funding return may plateau before recovering to pre-Brexit levels.

First Reported In

Update #7 · OQC's £260m sets European quantum record

GOV.UK / DSIT· 7 Jun 2026
Read original →
Causes and effects
This Event
UK Horizon Europe share rebounds to 9.3%
The 68% jump in Pillar 2 is a leading indicator for future UK tech transfer and spinout volume, rather than a diplomatic recovery metric.
Different Perspectives
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.
CDP Venture Capital
CDP Venture Capital
CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.
EDBI
EDBI
Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.
Forbion
Forbion
Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.
British Business Bank
British Business Bank
The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.
Stryker Corporation
Stryker Corporation
Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.